



#4 Receipt
Docket No.: 20731 US (C38435/120940)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
ASA KURA, et al.

Serial No.: 09/938,035

Filed: August 23, 2001

For: **MICROBIAL PROCESS FOR
PRODUCING L-ASCORBIC ACID, D-
ERYTHORBIC ACID, AND SALTS
THEREOF**

)
) Examiner: not yet assigned

)
) Art Unit: 1472

)
)
New York, New York
September 27, 2001

REQUEST FOR A CORRECTED FILING RECEIPT

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, D.C. 20231

Sir:

Please issue and send us a corrected filing receipt. A copy of the filing receipt we recently received for this case is enclosed, with the error noted thereon. The error in the filing receipt is as follows:

The foreign applications information is incorrect. Therefore, please change
"001180590.5 09/23/2000" to --00118059.5 08/23/2000--.

Appropriate correction is requested.

I hereby certify that this correspondence is being deposited with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Office of Initial Patent Examination, Customer Service Center Washington, D.C. 20231, on September 27, 2001.

Kevin C. Hooper, Reg. No. 40,402

Respectfully submitted,

By: _____
Kevin C. Hooper
Registration No. 40,402
BRYAN CAVE LLP
245 Park Avenue
New York, NY 10167-0034
(212) 692-1800
Fax: (212) 692-1900

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

UNITED STATES PATENT AND TRADEMARK OFFICE

ORIGINAL

APPLICATION NUMBER	09/938,035	FILING DATE	08/23/2001	GRP ART UNIT	1651	FIL FEE REC'D	1472	ATTY DOCKET NO	20731/120940	DRAWINGS	TOT CLAIMS	IND CLAIMS
--------------------	------------	-------------	------------	--------------	------	---------------	------	----------------	--------------	----------	------------	------------

6 20

CONFIRMATION NO. 1662

FILING RECEIPT



0000000006569373

Stephen M. Haracz, Esq.
Bryan Cave, LLP
245 Park Avenue
New York, NY 10167-0034

Date Mailed: 09/18/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Akira Asakura, Fujisawa-shi, JAPAN;
Tatsuo Hoshino, Kamakura-shi, JAPAN;
Masako Shinjoh, Kamakura-shi, JAPAN;

Assignment For Published Patent Application
ROCHE VITAMINS AG;

Domestic Priority data as claimed by applicant

Foreign Applications

EUROPEAN PATENT OFFICE (EPO) 001180597.5 09/23/2000

If Required, Foreign Filing License Granted 09/18/2001

Projected Publication Date: To Be Determined - pending completion of Sequence Disclosures

Non-Publication Request: No

Early Publication Request: No

Title

DOCKETED

Microbial process for producing L-ascorbic acid, D-erythronic acid, and salts thereof

ORIGINAL

Preliminary Class
435

Data entry by : AMARE, TSION

Team : OIPE

Date: 09/18/2001



LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
 Office of Initial Patent Examination
 Customer Service Center
 Washington, DC 20231

DATE

9-29-2001

INITIAL

H

